|
|
|
|
|
Patients with mCRC harboring BRAF V600 mutations exhibit overall survival rates half that of patients with wild-type BRAF 1 | |
|
|
|
|
mCRC, metastatic colorectal cancer.
Reference: 1. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012;7(10):e47054. | |
|
|
|
Founded on Science, Focused on Patients. | | | | |
| |
|
© 2019 Array BioPharma Inc. All rights reserved. NP-US-DE-0036 v1 | |
|
|
|
|
